ATRA - Atara Biotherapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5813.9M
Enterprise Value 3676.16M
Trailing P/E N/A
Forward P/E 1-2.77
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)3.06
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6-2.42

Trading Information

Stock Price History

Beta (3Y Monthly) 2.94
52-Week Change 3-61.15%
S&P500 52-Week Change 32.49%
52 Week High 343.95
52 Week Low 311.89
50-Day Moving Average 313.97
200-Day Moving Average 323.91

Share Statistics

Avg Vol (3 month) 3838.17k
Avg Vol (10 day) 31.09M
Shares Outstanding 553.76M
Float 37.6M
% Held by Insiders 14.86%
% Held by Institutions 1111.63%
Shares Short (Aug 15, 2019) 48.57M
Short Ratio (Aug 15, 2019) 48.8
Short % of Float (Aug 15, 2019) 426.43%
Short % of Shares Outstanding (Aug 15, 2019) 415.94%
Shares Short (prior month Jul 15, 2019) 49.4M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-46.53%
Return on Equity (ttm)-81.47%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -279.34M
Net Income Avi to Common (ttm)-278.96M
Diluted EPS (ttm)-6.07
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)190.14M
Total Cash Per Share (mrq)3.54
Total Debt (mrq)16.38M
Total Debt/Equity (mrq)7.05
Current Ratio (mrq)7.80
Book Value Per Share (mrq)4.95

Cash Flow Statement

Operating Cash Flow (ttm)-230.3M
Levered Free Cash Flow (ttm)-141.92M